Denali Therapeutics Inc’s filing revealed that its Director Krognes Steve E. unloaded Company’s shares for reported $1.9 million on Apr 01 ’24. In the deal valued at $20.50 per share,92,500 shares were sold. As a result of this transaction, Krognes Steve E. now holds 47,341 shares worth roughly $0.92 million.
Then, SATO VICKI L sold 1,666 shares, generating $33,487 in total proceeds. Upon selling the shares at $20.10, the Director now owns 119,709 shares.
Before that, SATO VICKI L sold 1,666 shares. Denali Therapeutics Inc shares valued at $30,604 were divested by the Director at a price of $18.37 per share. As a result of the transaction, SATO VICKI L now holds 121,375 shares, worth roughly $2.35 million.
Citigroup initiated its Denali Therapeutics Inc [DNLI] rating to a Buy in a research note published on December 13, 2023; the price target was $32. B. Riley Securities started covering the stock on September 06, 2023. It rated DNLI as “a Buy”.
Price Performance Review of DNLI
On Friday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 2.11% to $19.39. Over the last five days, the stock has lost -5.51%. Denali Therapeutics Inc shares have fallen nearly -9.65% since the year began. Nevertheless, the stocks have fallen -18.05% over the past one year. While a 52-week high of $33.31 was reached on 02/27/24, a 52-week low of $15.45 was recorded on 02/05/24. SMA at 50 days reached $18.92, while 200 days put it at $21.64. A total of 0.77 million shares were traded, compared to the trading of 0.83 million shares in the previous session.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 18.64, which if violated will result in even more drops to 17.89. On the upside, there is a resistance level at 19.78. A further resistance level may holdings at 20.17. The Relative Strength Index (RSI) on the 14-day chart is 47.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.84, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.57%. Stochastics %K at 16.93% indicates the stock is a buying.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on Mar 15, 2024, dropping by -2.44 million shares to a total of 8.38 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 10.82 million shares. There was a decline of -29.12%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 7.14% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.32.
The most recent change occurred on January 30, 2023 when SVB Securities began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
